The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) closed at $28.59 in the last session, down -2.19% from day before closing price of $29.23. In other words, the price has decreased by -$2.19 from its previous closing price. On the day, 0.72 million shares were traded. CRNX stock price reached its highest trading level at $29.55 during the session, while it also had its lowest trading level at $28.45.
Ratios:
We take a closer look at CRNX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 22.53 and its Current Ratio is at 22.53. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on July 10, 2025, initiated with a Neutral rating and assigned the stock a target price of $36.
On March 25, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $60.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 12 ’25 when Betz Stephen F. sold 97,483 shares for $32.23 per share. The transaction valued at 3,141,877 led to the insider holds 99,713 shares of the business.
STEPHEN BETZ bought 97,483 shares of CRNX for $3,151,625 on Jun 12 ’25. On Mar 19 ’25, another insider, Pizzuti Dana, who serves as the Chief Med and Dev Officer of the company, sold 2,515 shares for $34.20 each. As a result, the insider received 86,021 and left with 72,233 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRNX now has a Market Capitalization of 2678313984 and an Enterprise Value of 1455009920. For the stock, the TTM Price-to-Sale (P/S) ratio is 7439.76 while its Price-to-Book (P/B) ratio in mrq is 2.13. Its current Enterprise Value per Revenue stands at 1914.487 whereas that against EBITDA is -3.896.
Stock Price History:
The Beta on a monthly basis for CRNX is 0.33, which has changed by -0.42578828 over the last 52 weeks, in comparison to a change of 0.18569505 over the same period for the S&P500. Over the past 52 weeks, CRNX has reached a high of $62.53, while it has fallen to a 52-week low of $24.10. The 50-Day Moving Average of the stock is -7.28%, while the 200-Day Moving Average is calculated to be -28.46%.
Shares Statistics:
According to the various share statistics, CRNX traded on average about 792.18K shares per day over the past 3-months and 720540 shares per day over the past 10 days. A total of 93.53M shares are outstanding, with a floating share count of 86.72M. Insiders hold about 7.43% of the company’s shares, while institutions hold 104.88% stake in the company. Shares short for CRNX as of 1752537600 were 12236148 with a Short Ratio of 15.45, compared to 1749772800 on 10321299. Therefore, it implies a Short% of Shares Outstanding of 12236148 and a Short% of Float of 14.87.
Earnings Estimates
Its stock is currently analyzed by 11.0 different market analysts. The consensus estimate for the next quarter is -$1.17, with high estimates of -$1.02 and low estimates of -$1.32.
Analysts are recommending an EPS of between -$4.08 and -$5.07 for the fiscal current year, implying an average EPS of -$4.48. EPS for the following year is -$4.61, with 13.0 analysts recommending between -$3.13 and -$6.17.
Revenue Estimates
A total of 15 analysts have provided revenue estimates for CRNX’s current fiscal year. The highest revenue estimate was $9.14M, while the lowest revenue estimate was $1.7M, resulting in an average revenue estimate of $5.12M. In the same quarter a year ago, actual revenue was $1.04MBased on 15 analysts’ estimates, the company’s revenue will be $45.33M in the next fiscal year. The high estimate is $108.78M and the low estimate is $26M.
